Table 2. Study Characteristicsa.
| Authors’ Names | Year | Country | Dose, mg | Pethidine/Control (Number) | Variables | ||
|---|---|---|---|---|---|---|---|
| Time of Sensory Block, min | Time of Complete Motor Block, min | Analgesia Duration, min | |||||
| Farzi et al. ( 11 ) | 2014 | Iran | 25 | Pethidine (n = 65) | 4.5 ± 0.51 | 6.24 ± 0.66 | - |
| Control (n = 65) | 5.13 ± 0.29 | 6.86 ± 0.7 | - | ||||
| Atalay et al. ( 24 ) | 2010 | Turkey | 35 | Pethidine (n = 20) | 6.5 ± 1.5 | - | 403 ± 43 |
| Control (n = 20) | 6.1 ± 1.4 | - | 185 ± 20 | ||||
| 30 | Pethidine (n = 20) | 6.9 ± 1.7 | - | 315 ± 29 | |||
| Control (n = 20) | 6.1 ± 1.4 | - | 185 ± 20 | ||||
| 25 | Pethidine (n = 20) | 7 ± 1.7 | - | 295 ± 23 | |||
| Control (n = 20) | 6.1 ± 1.4 | - | 185 ± 20 | ||||
| Yu et al. ( 21 ) | 2002 | China | 10 | Pethidine (n = 20) | - | - | 234 ± 25 |
| Control (n = 20) | - | - | 125 ± 12 | ||||
| Kouzegaran et al. ( 25 ) | 2018 | Iran | 5 | Pethidine (n = 20) | - | - | 139 ± 45 |
| Control (n = 20) | - | - | 87.6 ± 30 | ||||
| Zebetian et al. ( 28 ) | 2013 | Iran | 10 | Pethidine (n = 35) | - | 6.95 ± 1.4 | - |
| Control (n = 35) | - | 7.35 ± 1.10 | - | ||||
| Kafle ( 31 ) | 1993 | Nepal | 10 | Pethidine (n = 25) | 5 ± 2 | - | - |
| Control (n = 25) | 5 ± 2 | - | - | ||||
| Hong and Lee ( 32 ) | 2005 | South Korea | 10 | Pethidine (n = 30) | 4.8 ± 0.2 | 7.1 ± 1.5 | - |
| Control (n = 30) | 5.75 ± 0.3 | 7.2 ± 1.7 | - | ||||
| Shrestha et al. ( 23 ) | 2007 | Nepal | 10 | Pethidine (n = 30) | - | - | 510 ± 32 |
| Control (n = 30) | - | - | 96 ± 12 | ||||
| Roy et al. ( 34 ) | 2004 | Canada | 15 | Pethidine (n = 20) | 4.5 ± 0.41 | 6.75 ± 0.21 | |
| Control (n = 20) | 5.1 ± 0.39 | 6.95 ± 0.29 | |||||
| Mohamad et al. ( 35 ) | 2018 | Egypt | 25 | Pethidine (n = 25) | - | - | 169.2 ± 7.59 |
| Control (n = 25) | - | - | 93 ± 17 | ||||
aValues are expressed as mean ± SD.